Back to top

Karyopharm price target lowered to $11 from $14 at Jefferies

Jefferies lowered the firm’s price target on Karyopharm (KPTI) to $11 from $14 and keeps a Buy rating on the shares. The company’s latest update is...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Karyopharm Therapeutics Inc. (KPTI)